Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Histamine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    198 result(s) found for: Histamine. Displaying page 3 of 10.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-005362-35 Sponsor Protocol Number: VB-01-DPHLOLEG Start Date*: 2013-04-09
    Sponsor Name:Instituto de Inmunología y Alergia INMUNAL SAU
    Full Title: Biological standardization of pollen of Phleum pratense, Olea europaea, mite extract Dermatophagoides pteronyssinus and animal allergen Felis domesticus. Open label, single center, phase II study.
    Medical condition: Biological standardization for allergenic extracts in patients with hipersensibility to extracts
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10001708 Allergic conditions HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002728-94 Sponsor Protocol Number: NK-CML-01 Start Date*: 2017-11-16
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: A phase I/II, open-label study of safety, immune activation and efficacy of histamine dihydrochloride and low-dose interleukin-2 in adult tyrosine kinase inhibitor-treated patients with chronic mye...
    Medical condition: Chronic Myeloid Leukemia (CML)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-002807-33 Sponsor Protocol Number: NLA-C003P Start Date*: 2004-11-09
    Sponsor Name:Biolipox AB
    Full Title: A double blind, randomized, cross-over, placebo controlled study, evaluating the time-to-onset of action of BLX000441-002 nasal spray in healthy volunteers.
    Medical condition: healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003408-20 Sponsor Protocol Number: 6080-PR-PRI-146 Start Date*: 2007-07-16
    Sponsor Name:Laboratorios Leti, S.L.unipersonal
    Full Title: Extracto alergénico de Salsola oppositifolia Determinación de la potencia alergénica in vivo en unidades equivalentes de histamina (HEP)
    Medical condition: Alergia frente a la hierba salsola oppositifolia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001939-31 Sponsor Protocol Number: 101-PR-PRI-196 Start Date*: 2013-02-13
    Sponsor Name:LABORATORIOS LETI S.L.U
    Full Title: Biological standardization of Dermatophagoides pteronyssinus allergen extract to determine the biological activity in histamine equivalent units (HEP).
    Medical condition: Allergy to Dermatophagoides pteronyssinus
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-002808-18 Sponsor Protocol Number: AL0701rP Start Date*: 2007-10-31
    Sponsor Name:ALLERGOPHARMA JOACHIM GANZER KG
    Full Title: A double-blind placebo controlled dose-response study for evaluation of safety and efficacy of immunotherapy with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense)...
    Medical condition: ICD classification code: J45.0 and J30.1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039085 Rhinitis allergic LLT
    9.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005406-96 Sponsor Protocol Number: AB20006 Start Date*: 2022-10-07
    Sponsor Name:AB Science
    Full Title: A 24-week, multicenter, randomized, double blind, placebo-controlled, dose-range finding phase II study to compare efficacy and safety of oral masitinib to placebo in treatment of patients with sev...
    Medical condition: severe mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatment
    Disease: Version SOC Term Classification Code Term Level
    20.1 10005329 - Blood and lymphatic system disorders 10075217 Mast cell activation syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-004743-22 Sponsor Protocol Number: FFR30006 Start Date*: Information not available in EudraCT
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mc...
    Medical condition: Vasomotor/Idiopathic Rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004744-43 Sponsor Protocol Number: FFR30007 Start Date*: Information not available in EudraCT
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mc...
    Medical condition: Vasomotor/Idiopathic Rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002193-31 Sponsor Protocol Number: PollenLITE Start Date*: 2012-08-08
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas' NHS Foundation Trust
    Full Title: A Randomised, Double-blind, Single-centre, Controlled Trial of Low Dose Intradermal Allergen Immunotherapy in Adults with Seasonal Allergic Rhinitis
    Medical condition: Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001310-15 Sponsor Protocol Number: 6058-PR-PRI-200 Start Date*: 2013-10-28
    Sponsor Name:LABORATORIOS LETI, S.L.U
    Full Title: Biological standardization of Artemisia vulgaris allergen extract to determine the biological activity in histamine equivalent units (HEP).
    Medical condition: Allergy to Artermisia vulgaris
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004870 10036019 Pollen allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001309-98 Sponsor Protocol Number: 608-PR-PRI-199 Start Date*: 2015-07-09
    Sponsor Name:LABORATORIOS LETI, S.L.Unipersonal
    Full Title: Biological standarization of Cupressus arizonica allergen extract to determine the biological activity in histamine equivalent units (HEP)
    Medical condition: Allergy to Cupressus arizonica
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004870 10036019 Pollen allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-005529-25 Sponsor Protocol Number: API-EAG-2021-01 Start Date*: 2022-10-14
    Sponsor Name:ASAC Pharmaceutical Inmunology, S.A.
    Full Title: In vivo Biological Standardization of Gramineae Allergenic Extracts
    Medical condition: Biological standarization for allergenic extracts in patients with hipersensibility to extract
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10001708 Allergic conditions HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007657-31 Sponsor Protocol Number: MIARCU 01/2008 Start Date*: 2008-06-23
    Sponsor Name:Charité-University Berlin
    Full Title: Efficacy and safety of Miltefosine in antihistamine resistant chronic urticaria
    Medical condition: Urticaria characterized by mast cell and histamine-dependent wheal and flair type-skin responses associated with severe pruritus. The disease is very common and not always easy to treat. Mainstay t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003930-41 Sponsor Protocol Number: DME_01 Start Date*: 2007-11-20
    Sponsor Name:Curalogic A/S
    Full Title: Assessment of the Maximal Tolerated Dose of a Microencapsulated House Dust Mite (Dermatophagoides pteronyssinus and Dermatophagoides farinae) Extract (MHDME) in Subjects with House Dust Mite Allerg...
    Medical condition: Allergic rhinoconjunctivitis due to house mite dust allergy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004222-93 Sponsor Protocol Number: GPE 02 Start Date*: 2006-11-28
    Sponsor Name:Curalogic A/S
    Full Title: Assessment of the Maximal Tolerated Dose of a Microencapsulated Grass (Phleum pratense) Pollen Extract (MGPE) in Subjects with Grass Pollen Allergy in a Randomized, Double-Blind, Placebo-Controlled...
    Medical condition: Treatment of seasonal allergic rhinitis to grass pollen.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001879-73 Sponsor Protocol Number: E3810-A001-202 Start Date*: 2016-06-27
    Sponsor Name:Eisai Medical Research Inc.
    Full Title: Safety and Efficacy of Rabeprazole in the Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients
    Medical condition: Gastroesophageal Reflux Disease
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-006726-26 Sponsor Protocol Number: 101266 Start Date*: 2007-03-05
    Sponsor Name:Orexo AB
    Full Title: An open-label randomised observer-blind study to evaluate 24-hour intragastric pH profile at day 1 and day 14 during treatment with a fixed combination of a histamine type 2 receptor antagonist and...
    Medical condition: Frequent heartburn
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001130-16 Sponsor Protocol Number: IC011RUP/4/04 Start Date*: Information not available in EudraCT
    Sponsor Name:J. URIACH & COMPAÑIA
    Full Title: 12 months long term safety and tolerability of Rupatadine 10 mg in the treatment of moderate-severe persistent allergic rhinitis.
    Medical condition: Perennial allergic rhinitis is a autoinmuno disease and its pathopshysiology is based on released of several mediators, such as histamine. The symptoms include: itchy eyes and palate, runny nose, s...
    Disease: Version SOC Term Classification Code Term Level
    6 10039094 pt
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002872-41 Sponsor Protocol Number: ELR100710 Start Date*: 2005-10-18
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Study to Validate Key Therapeutic Targets and Biomarkers during Allergen Exposure in Subjects with Allergic Rhinitis
    Medical condition: Seasonal allergic rhinitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 10:22:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA